kabutan

ONO PHARMA, First Half Net Income Increases by 7%, Jul-Sep Net Income Increases by 77%

Thu Oct 30, 2025 12:00 pm JST Earnings

4528 ONO PHARMACEUTICAL CO., LTD. 【IFRS】

Earnings Report

ONO PHARMACEUTICAL CO., LTD. <4528> [TSE Prime] announced its financial results (based on IFRS) at noon (12:00) on October 30th. The consolidated net income for the cumulative second quarter of the fiscal year ending March 2026 (April to September) increased 7.1% from the same period last year, reaching 40.0 billion yen. Progress toward the full-year plan of 67.0 billion yen was 59.8%, almost the same as the five-year average of 59.7%.

Based on the first-half performance announced by the company and the unchanged full-year plan, our calculation indicates that the consolidated net income for the October to March period (second half) is expected to surge 2.1 times that of the same period last year, reaching 26.9 billion yen.

In the most recent three-month period, from July to September (2Q), the consolidated net income increased 77.3% from the same period last year, reaching 22.4 billion yen. The operating profit margin jumped from 14.8% in the same period last year to 23.2%.

Kabutan News

Actual Results

Accumulated Results 2nd Quarter
Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Progress Rate vs. First Half Announce Accounting Standards
Apr - Sep, 2023 258,713 97,036 99,296 74,491 153.3 60.6 Nov 1, 2023 IFRS
Apr - Sep, 2024 240,339 48,788 47,544 37,435 79.7 80.1 Oct 31, 2024 IFRS
Apr - Sep, 2025 257,136 52,069 52,175 40,089 85.3 61.4 Oct 30, 2025 IFRS
YoY +7.0% +6.7% +9.7% +7.1% +7.1%

First Half Results vs. Previous Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Apr - Sep, 2025 Guidance ー ー ー ー － 40 May 8, 2025 IFRS
Apr - Sep, 2025 Results 257,136 52,069 52,175 40,089 85.3 40 Oct 30, 2025 IFRS
Revision Rate － － － － －

Current Period Guidance

Second Half Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Oct - Mar, 2024 246,532 10,959 11,784 12,612 26.9 40 May 8, 2025 IFRS
Oct - Mar, 2025 Guidance 232,864 32,931 32,825 26,911 57.3 40 Oct 30, 2025 IFRS
YoY -5.5% +200.5% +178.6% +113.4% +113.3%

Current Period Guidance

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Adj. Dividend Announce Accounting Standards
Mar, 2024 502,672 159,935 163,734 127,977 266.6 80 May 9, 2024 IFRS
Mar, 2025 486,871 59,747 59,328 50,047 106.6 80 May 8, 2025 IFRS
Mar, 2026 Guidance 490,000 85,000 85,000 67,000 142.6 80 May 8, 2025 IFRS
YoY +0.6% +42.3% +43.3% +33.9% +33.8%

Quarterly Results

Fiscal Year Revenue Operating Profit Ordinary Profit Net Profit Adj. EPS Operating Profit Margin Announce Accounting Standards
Jul - Sep, 2024 122,664 18,098 14,234 12,641 26.9 14.8 Oct 31, 2024 IFRS
Oct - Dec, 2024 134,223 21,966 24,493 19,157 40.8 16.4 Feb 3, 2025 IFRS
Jan - Mar, 2025 112,309 -11,007 -12,709 -6,545 -13.9 -9.8 May 8, 2025 IFRS
Apr - Jun, 2025 127,536 21,995 22,650 17,673 37.6 17.2 Aug 1, 2025 IFRS
Jul - Sep, 2025 129,600 30,074 29,525 22,416 47.7 23.2 Oct 30, 2025 IFRS
YoY +5.7% +66.2% +107.4% +77.3% +77.2%

Related Articles